TABLE 9.
Rank order (SUCRA) of 1L aRCC combination therapies for OS and PFS across eligible NMAs.
| Endpoint | NMA | Ranking [ranking probability (%)] | |||
|---|---|---|---|---|---|
| CAB + NIV | AXY + PEM | LEN + PEM | NIV + IPI | ||
| OS overall population | current study | 2 (64.0%) | 4 (53.5%) | 1 (75.5%) | 3 (56.9%) |
| Riaz et al. (2021) | 2 (82.35%) | 3 (80.22%) | 1 (83.0%) | 4 (79.35%) | |
| Quhal11 a | 1 (75.73%) | 3 (64.96%) | 2 (67.46%) | 4 (63.58%) | |
| Nocera15 a | 1 (77%) | 3 (57%) | 2 (63%) | 4 (53%) | |
| Bosma et al. (2022) | 1 (82%) | 3 (68%) | 2 (72%) | 4 (66%) | |
| OS IMDC favorable risk population | current study | 1 (56.1%) | 4 (36.2%) | 2 (42.9%) | n.e |
| Riaz et al. (2021) | 3 (60.24%) | 6 (37.34%) | 7 (31.49%) | 4 (53.54%) | |
| Quhal11 a | 2 (55,27%) | 5 (45.39%) | 6 (43.43%) | 3 (52.09%) | |
| Bosma et al., 2022) | 2 (62%) | 5 (40%) | 6 (33%) | 3 (56%) | |
| OS IMDC intermediate or poor risk population |
current study | 2 (63.4%) | 3 (61.1%) | 1 (77.9%) | 4 (47.3%) |
| Riaz et al. (2021) | 1 (82.03%) | 3 (69.56%) | 2 (73.14%) | 4 (65.1%) | |
| Quhal11 a | 2 (83.52%) | 5 (31.13%) | 1 (86.53%) | 3 (49.24%) | |
| Bosma - intermediate Bosma et al. (2022) | 3 (60%) | 1 (78%) | 4 (56%) | 2 (71%) | |
| Bosma - poor Bosma et al. (2022) | 2 (80%) | 5 (42%) | 1 (89%) | 4 (44%) | |
| PFS overall population | current study | 2 (73.5%) | 3 (51.1%) | 1 (99.8%) | 4 (24.7%) |
| Riaz et al. (2021) | 3 (85.06%) | 5 (66.49%) | 1 (98.07%) | 7 (44.27%) | |
| Quhal11 a | 2 (82.16%) | 4 (51.63%) | 1 (99.06%) | 6 (23.72%) | |
| Nocera15 a | 4 (39%) | 3 (52%) | 1 (79%) | 2 (64%) | |
| Bosma et al. (2022) | 2 (84%) | 4 (56%) | 1 (99%) | 6 (24%) | |
| PFS IMDC favorable risk population | current study | 2 (50.8%) | 3 (46.8%) | 1 (98.9%) | n.e |
| Riaz et al. (2021) | 2 (66.45%) | 5 (45.64%) | 1 (96.37%) | 7 (0.12%) | |
| Quhal11 a | 2 (59.67%) | 4 (58.75%) | 1 (92.11%) | 6 (10.94%) | |
| Bosma et al. (2022) | 2 (68%) | 4 (47%) | 1 (96%) | 6 (0%) | |
| PFS IMDC intermediate or poor risk population | current study | 2 (75.5%) | 3 (45,9%) | 1 (95.6%) | 4 (32.9%) |
| Riaz et al. (2021) | 2 (78.47%) | 5 (41.76%) | 1 (95.44%) | 6 (31.72%) | |
| Quhal11 a | 2 (80.79%) | 4 (40.71%) | 1 (97.55%) | 5 (32.83%) | |
| Bosma - intermediate Bosma et al. (2022) | 2 (74%) | 3 (42%) | 1 (98%) | n.e | |
| Bosma - poor Bosma et al. (2022) | 2 (75%) | 4 (41%) | 1 (89%) | n.e | |
a
Quhal and Nocera reported p-value instead of SCORE (%); n.e, not estimated; AXY, axitinib; CAB, cabozantinib; IPI, ipilimumab; LEN, lenvatinib; NIV, nivolumab; PEM, pembrolizumab